Cognition Therapeutics company info

What does Cognition Therapeutics do?
Cognition Therapeutics (NASDAQ:CGTX) is a biopharmaceutical company focused on the discovery and development of innovative therapies for neurodegenerative diseases. Its main projects target the underlying pathophysiology of diseases such as Alzheimer's, showcasing a commitment to addressing significant unmet medical needs in the aging population. The company's objectives revolve around advancing its lead candidate, CT1812, through clinical trials, aiming to demonstrate its potential in modifying the course of Alzheimer’s disease and related conditions. By leveraging its proprietary drug discovery platform, Cognition Therapeutics is dedicated to expanding its pipeline to encompass treatments for other central nervous system disorders, aspiring to improve the lives of patients worldwide through groundbreaking science and medicine.
Cognition Therapeutics company media
Company Snapshot

Is Cognition Therapeutics a public or private company?

key
Ownership
Public

How many people does Cognition Therapeutics employ?

people
Employees
25

What sector is Cognition Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Cognition Therapeutics?

location pin
Head Office
Pittsburgh, United States

What year was Cognition Therapeutics founded?

founded flag
Year Founded
2007
What does Cognition Therapeutics specialise in?
/Alzheimer's Treatment /Drug Discovery /Neurology Research /Clinical Trials /Patented Therapies /Biopharmaceutical Company

What are the products and/or services of Cognition Therapeutics?

Overview of Cognition Therapeutics offerings
Development of CT1812, a small molecule designed to protect against Alzheimer's Disease by displacing beta-amyloid oligomers from neuron receptors.
Dry age-related macular degeneration (dry AMD): CT1812 is also being investigated for this eye disease that causes vision loss.
Dementia with Lewy bodies: This is another form of dementia that CT1812 is being evaluated for.
Investigation into therapies for geographic atrophy, utilizing novel mechanisms to reduce disease progression.
Discovery and development of other product candidates: They are focused on synucleinopathies, a class of neurodegenerative diseases that includes Parkinson's disease and Multiple System Atrophy.
Development of diagnostic tools and biomarkers for early detection of cognitive impairments and monitoring disease progression.

Who is in the executive team of Cognition Therapeutics?

Cognition Therapeutics leadership team
  • Ms. Lisa  Ricciardi
    Ms. Lisa Ricciardi
    CEO, President & Director
  • Dr. Anthony O. Caggiano M.D., Ph.D.
    Dr. Anthony O. Caggiano M.D., Ph.D.
    Chief Medical Officer and Head of R&D
  • Mr. John Brendan Doyle
    Mr. John Brendan Doyle
    Chief Financial Officer
  • Dr. Steven A. Weissman Ph.D.
    Dr. Steven A. Weissman Ph.D.
    VP & Head of CMC